Why Merck KGaA is paying a 130% premium for Silence's gene-silencing technology
FROM THE WIRE · FINANCE.YAHOO.COM
Silence Therapeutics stock surges as Merck KGaA agrees to acquire the RNA drugmaker for over $1 billion. Continue Reading
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishThe steep premium supports the target stock, and the deal is valued at over $1 billion.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Silence Therapeutics stock surges as Merck KGaA agrees to acquire the RNA drugmaker.
- 02The deal is valued at over $1 billion.
- 03The stock is rising sharply on the news.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Silence Therapeutics plc19.57 USD+0.05%today +125.52%Positive Merck KGaA144.35 EURMarket closedtoday +0.03%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets